CONNECTs
Our programmes
- See All
- Podcast
- Experts knowledge share
- E-learning
- Video
- Publication
- Other
Key Publication Snapshot 5: TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
Experts
Dr Luca Toschi-
Downloadable
Resources -
5 MIN
-
Sep 2021
Downloadable 
5 MIN
Sep 2021 
Learn about the patient journey through diagnosis and treatment of NTRK fusion positive cancer
Experts
Prof. Ulrik Lassen, Assoc. Prof. Caterina Marchiò-
5 MIN
-
Sep 2021
-
Downloadable
Resources -
5 MIN
-
Sep 2021
Current opinions on how to identify and treat NTRK fusion positive cancer
Experts
Prof. David Hong, Prof. Ezra Cohen, Prof. Frédérique Penault-Llorca-
Downloadable
Resources -
5 MIN
-
Sep 2021
-
Downloadable
Resources -
5 MIN
-
Sep 2021
Key Publication Snapshot 3 – Characterisation of adverse events caused by TRK inhibitor therapy
Experts
Prof. Ezra Cohen-
Downloadable
Resources -
5 MIN
-
Sep 2021
Highlights BY NTRK CONNECT – Key NTRK fusion abstracts from ASCO and WCGIC 2021
Experts
Prof. Andrea Sartore-Bianchi-
Downloadable
Resources -
5 MIN
-
Sep 2021
Highlights BY NTRK CONNECT – Key NTRK fusion abstracts from USCAP, ELCC and AACR 2021
Experts
Dr Fernando Santini-
Downloadable
Resources -
5 MIN
-
Sep 2021
NTRK CONNECT Update from ESMO 2019
Experts
Assoc. Prof. Caterina Marchiò-
Downloadable
Resources -
5 MIN
-
Sep 2021
Key Publication Snapshot 1 – Larotrectinib and Entrectinib efficacy and safety profile in solid tumours
Experts
Prof. Andrea Sartore-Bianchi-
Downloadable
Resources -
5 MIN
-
Sep 2021
NTRK gene fusions, TRK inhibitors and testing approaches BluePrint
Experts
Prof. Andrea Sartore-Bianchi, Prof. Fernando López-Ríos, Assoc. Prof. Gerald Prager-
Downloadable
Resources -
5 MIN
-
Sep 2021
Key Publication Snapshot 2 – Identifying patients with NTRK fusion cancer
Experts
Prof. Fernando López-Ríos-
Downloadable
Resources -
5 MIN
-
Sep 2021
An Experts’ Forum in Tokyo and Singapore on DDR and PARP inhibition
Experts
Prof. Keiichi Fujiwara, Prof. Simon Boulton, Dr Shinji Ohno, Dr Rebecca Dent, Prof. Charlie Gourley-
Downloadable
Resources -
60 MIN
-
Sep 2021
Moving from PARP Inhibition to Targeting DNA Repair and DDR in Cancer Therapy
Experts
Dr Judith Balmaña, Dr Rebecca Dent, Prof. Simon Boulton, Prof. Sibylle Loibl, Prof. Eric Pujade-Lauraine, Prof. Charlie Gourley, Dr Violeta Serra, Prof. Jonathan A. Ledermann-
Downloadable
Resources -
10 MIN
-
Sep 2021
Video
Understand the MoA of PARP inhibitors and targeting DNA Damage Response (DDR)
Experts
Dr Robert L. Coleman, Prof. Simon Boulton-
Downloadable
Resources -
5 MIN
-
Sep 2021
Interactive e-learning
The Role of PARP Inhibition in Clinical Practice
Experts
Prof. Jonathan A. Ledermann, Dr Rebecca Dent, Dr Robert L. Coleman, Prof. Eric Pujade-Lauraine-
60 MIN
-
Sep 2021
Other
The Role of DDR and PARP inhibition (PARPi) in Oncology – BluePrints
Experts
Dr Violeta Serra, Prof. Jonathan A. Ledermann, Prof. Eric Pujade-Lauraine, Prof. Simon Boulton, Dr Mark J. O'Connor, Prof. Charlie Gourley, Dr Judith Balmaña, Prof. Sibylle Loibl-
Downloadable
Resources -
MIN
-
Sep 2021
PARP inhibition and DNA Damage Response (DDR)
This comprehensive resource looks at PARP inhibition and DDR as therapeutic targets across multiple tumour types
Experts
Prof. Simon Boulton, Dr Violeta Serra, Dr Judith Balmaña, Prof. Charlie Gourley-
30 MIN
-
Oct 2021
Update From ASCO 2022 – Selected LBAs
COR2ED brings you an update on the late breaker plenary sessions from ASCO 2022
Experts
Dr Rebecca Dent, Prof. Chiara Cremolini, Asst. Prof. Hans Lee, Prof. Jonathan Trent-
7 MIN
-
May 2022
COR2ED at ESMO 2022
We celebrate our 10-year anniversary at the COR2ED booth during ESMO 2022. In 10 years, 500,000 healthcare professionals have trusted our educational programmes.
-
2 MIN
-
Sep 2022
-
Downloadable
Resources -
5 MIN
-
Sep 2022
Update From San Antonio Breast Cancer Symposium 2022
COR2ED presents an update on selected General Sessions from SABCS 2022
Experts
Dr Santiago Escrivá de Romaní-
5 MIN
-
Dec 2022
Conference update
Episode
1
of 6
Listen to Expert Insights on Late-Breaking Data from ASCO 2023
Episode 1: Non-Small-Cell Lung Cancer Update: ADAURA trial
Experts
Dr Mansoor Raza Mirza, Dr Paolo Tarantino, Prof. Alexey V Danilov, Prof. Mark Socinski, Prof. Evan Yu, Prof. Thomas Powles, Assoc. Prof. Gerald Prager-
2 MIN
-
Jun 2023
Video
Episode
1
of 4
New Oral Endocrine Therapy Options for Patients with Advanced or Metastatic ER+ Breast Cancer
Episode 1: Overview of Clinical Data of SERDs & Their Place in Treatment Landscape
Experts
Dr Sara Tolaney, Dr Aditya Bardia, Prof. Frédérique Penault-LlorcaEndorsed by
-
Downloadable
Resources -
18 MIN
-
Jul 2023
Podcast
Episode
1
of 3
Oral SERDs in ER+ breast cancer
Episode 1: Efficacy, safety and treatment landscape
Experts
Prof. Shaheenah Dawood, Assoc. Clinical Professor Rena CallahanEndorsed by
-
MIN
-
Jul 2023
Interactive patient case
Episode
1
of 2
Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 1
An interactive patient case video series from breast cancer specialists
Experts
Dr Elisa AgostinettoEndorsed by
-
15 MIN
-
Sep 2023
Video
Navigating the ER+ Breast Cancer Journey: Oral SERDs and the Treatment Landscape
Follow a patient's breast cancer journey from diagnosis to treatment options
Experts
Prof. Francois-Clement BidardEndorsed by
-
Downloadable
Resources -
7 MIN
-
Oct 2023
Interactive patient case
Episode
2
of 2
Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 2
An interactive patient case video series from breast cancer specialists
Experts
Prof. Valentina GuarneriEndorsed by
-
15 MIN
-
Oct 2023
Tweetorial
Tweetorial video: Navigating ER+ metastatic breast cancer
Explore a patient case from testing, diagnosis and treatment
Experts
Dr Paolo TarantinoEndorsed by
-
9 MIN
-
Nov 2023
Video
Actionable fusions in solid tumours
An overview of gene fusions, gold standard detection methods and treatment implications
Experts
Prof. Fernando López-Ríos-
Downloadable
Resources -
3 MIN
-
Dec 2023
Video
ER+ metastatic breast cancer: Elacestrant and beyond
Follow a patient's journey during and post-elacestrant treatment for ER+/HER2- metastatic breast cancer
Experts
Prof. Maria Vittoria DieciEndorsed by
-
Downloadable
Resources -
5 MIN
-
Feb 2024
Conference update
ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium
Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer
Experts
Prof. Valentina Guarneri, Prof. Matteo Lambertini, Prof. Federico Rojo-
Downloadable
Resources -
6 MIN
-
Mar 2024
Tweetorial
Tweetorial video: Treating ER+/HER2-low metastatic breast cancer, 2L and beyond
Journey through a patient case from testing and diagnosis to treatment and AE management
Experts
Dr Aditya BardiaEndorsed by
-
11 MIN
-
Apr 2024
Conference update
Episode
2
of 4
ASCO 2024 breast cancer highlights
How could the data impact clinical practice?
Experts
Prof. Shaheenah Dawood-
3 MIN
-
Jun 2024
Conference update
ESMO 2024: New data on GI, lung, HCC, breast and GU cancers
Renowned medical experts share their insights into new data presented at ESMO 2024
-
Downloadable
Resources -
5 MIN
-
Sep 2024
Conference update
Rezatapopt in TP53 Y220C mutated metastatic breast cancer: PYNNACLE phase 1/2 update
Exploring emerging treatment strategies presented at SABCS 2024
Experts
Prof. Frédérique Penault-Llorca, Dr Ecaterina E Dumbrava-
Downloadable
Resources -
5 MIN
-
Dec 2024
Video
Elacestrant in ER+/HER2- metastatic breast cancer
An expert overview of the EMERALD subgroup analysis
Experts
Dr Virginia Kaklamani-
Downloadable
Resources -
4 MIN
-
Dec 2024
Video
Recent advances in precision oncology and future implications
Two emerging and two established targets
Experts
Prof. David Hong-
Downloadable
Resources -
4 MIN
-
Dec 2024